Allen & Gledhill has announced the establishment of two new practices – technology disputes, and healthcare, life sciences and pharmaceuticals in the Singapore office.
The technology disputes practice will be led by partners Tan Kai Liang, deputy co-head of the firm’s international arbitration practice, and Melissa Mak. It will complement the existing technology and corporate intellectual property practice, and provide advice on tech-related matters.
The healthcare, life sciences and pharmaceuticals practice will be headed by partners Mak Wei Munn and Christopher Koh, who also serves as deputy head of the corporate M&A department. The team will advise on cross-border M&A, healthcare regulations and requirements, corporate reorganisation and restructuring, commercial agreements and contracts, establishment of healthcare infrastructure and other operational agreements.
Managing partner Jerry Koh said the launch of the two new practices was partly influenced by developments discussed at the 27th Asean Economic Community Council Meeting and the 48th Asean Summit.
“Our firm is always on the lookout for ways we can enhance our value offerings to clients and meet the evolving needs of the market. One way we do so is through vigilantly and constantly augmenting our offerings to address critical needs and capture emerging opportunities for our clients,” he told Asia Business Law Journal.
“As such, we proactively moved to set up our healthcare, life sciences and pharmaceuticals practice, and our technology disputes practice, to consolidate our expertise and enhance our capabilities in these areas.”
Jerry Koh added that the new practices would be able to leverage Allen & Gledhill’s network of associate firms and offices in Singapore, Malaysia, Myanmar, Indonesia, Vietnam and China to “provide fit-for-purpose counsel on any matter our clients may have across the business landscape”.
